Abivax SA (Euronext Paris: FR0012333284 - ABVX) ("Abivax" or the "Company") today announced updated business and operational goals along with changes to Abivax's overall strategy , focused on preparing Abivax for the potential commercialization of its investigational lead asset, obefazimod, in IBD.